4 withdrawn. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Withdrawn 4 |
Follow Brain Tumor: new trials by email Literature Review of Brain Tumor trials Research Report on Brain Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas Control Group - Standard of care neurosurgical resection, MRF/MRI infiltration guidance for extended resection - Glioblastoma, Brain Tumor | Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2025-12-01 | 2026-07-01 | |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors tepotinib, tepotinib plus osimertinib - Brain Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-02-27 | 2024-04-17 | |
| A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma Temozolomide, Tamoxifen, Maprotiline - Glioblastoma, Brain Tumor | Phase 1 | Withdrawn | University of Rochester | 2022-06-01 | 2022-08-22 | |
| A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors Pazopanib (GW786034) - Sarcoma, Neuroblastoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2010-05-10 | 2017-07-02 |
Brain Neoplasms (4) · Glioblastoma (2) · Neoplasms (1) · Neuroblastoma (1) · Osteosarcoma (1) · Sarcoma (1) · Wilms Tumor (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Central Nervous System Neoplasms (4) · Neoplasms by Site (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Astrocytoma (2) · Glioma (2)
Maprotiline (1) · Tamoxifen (1) · Temozolomide (1) · osimertinib (1) · pazopanib (1) · tepotinib (1)
Case Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Rochester (1)
United States (2)
Barbara O'Brien, MD (1) · Chaitra Badve, MD (1) · Nimish Mohile, MD (1) · Tiffany Hodges, MD (1)